162 related articles for article (PubMed ID: 2568651)
1. Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation.
Jann MW; Fidone GS; Hernandez JM; Amrung S; Davis CM
Psychiatry Res; 1989 May; 28(2):153-9. PubMed ID: 2568651
[TBL] [Abstract][Full Text] [Related]
2. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
3. Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates.
Douyon R; Angrist B; Peselow E; Cooper T; Rotrosen J
Am J Psychiatry; 1989 Feb; 146(2):231-4. PubMed ID: 2563211
[TBL] [Abstract][Full Text] [Related]
4. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
Chouinard G; Annable L; Campbell W
J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
[TBL] [Abstract][Full Text] [Related]
5. Effect of neuroleptic withdrawal on plasma prolactin: a possible marker of receptor adaptation.
Kirkpatrick B; Buchanan RW; Maeda K; Carpenter WT; Jauch D; Tamminga CA
Biol Psychiatry; 1989 Jun; 26(2):131-8. PubMed ID: 2567610
[TBL] [Abstract][Full Text] [Related]
6. A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia. With particular reference to drug resistance.
Altamura AC
Schizophr Res; 1993 Jan; 8(3):187-98. PubMed ID: 8094628
[TBL] [Abstract][Full Text] [Related]
7. Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia.
Ulrich S; Neuhof S; Braun V; Meyer FP
Int Clin Psychopharmacol; 1999 Jul; 14(4):219-28. PubMed ID: 10468314
[TBL] [Abstract][Full Text] [Related]
8. Increased incidence of dyskinesias and other behavioral effects of re-exposure to neuroleptic treatment in social colonies of Cebus apella monkeys.
Linn GS; Lifshitz K; O'Keeffe RT; Lee K; Camp-Lifshitz J
Psychopharmacology (Berl); 2001 Jan; 153(3):285-94. PubMed ID: 11271400
[TBL] [Abstract][Full Text] [Related]
9. Prolonged haloperidol and reduced haloperidol plasma concentrations after decanoate withdrawal.
Chang WH; Lin SK; Juang DJ; Chen LC; Yang CH; Hu WH; Chien CP; Lam YW; Jann MW
Schizophr Res; 1993 Mar; 9(1):35-40. PubMed ID: 8461270
[TBL] [Abstract][Full Text] [Related]
10. Induction of tardive dyskinesia in Cebus apella and Macaca speciosa monkeys: a review.
Domino EF
Psychopharmacology Suppl; 1985; 2():217-23. PubMed ID: 2860660
[TBL] [Abstract][Full Text] [Related]
11. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
Roose K
Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
[TBL] [Abstract][Full Text] [Related]
12. Severe extrapyramidal side effects when discontinuing clozapine and starting haloperidol.
Bobba R
Can J Psychiatry; 1997 Jun; 42(5):530. PubMed ID: 9220119
[No Abstract] [Full Text] [Related]
13. Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables.
Lane HY; Chang WH; Chang YC; Hu OY; Lin HN; Jann MW; Hu WH
Psychiatry Res; 1997 Sep; 72(2):127-32. PubMed ID: 9335203
[TBL] [Abstract][Full Text] [Related]
14. Use of aripiprazole in tardive dyskinesia: an open label study of six cases.
Rajarethinam R; Dziuba J; Manji S; Pizzuti A; Lachover L; Keshavan M
World J Biol Psychiatry; 2009; 10(4 Pt 2):416-9. PubMed ID: 19492247
[TBL] [Abstract][Full Text] [Related]
15. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Citrome L; Jaffe A; Levine J
Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
[TBL] [Abstract][Full Text] [Related]
16. Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.
Uchida T; Suzuki T; Sakurai H; Tsutsumi C; Den R; Mimura M; Uchida H
Int Clin Psychopharmacol; 2013 Sep; 28(5):261-6. PubMed ID: 23820334
[TBL] [Abstract][Full Text] [Related]
17. Atypical antipsychotics, tardive dyskinesia, and D(2) receptors.
Duggal HS; Mendhekar DN
Am J Psychiatry; 2006 Aug; 163(8):1449-50. PubMed ID: 16877664
[No Abstract] [Full Text] [Related]
18. [Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics].
Sejil I; Oumaya A; Bouguerra C; Mehdi F; Bellaaj R; Gallali S
Encephale; 2013 May; 39 Suppl 1():S36-41. PubMed ID: 23219594
[TBL] [Abstract][Full Text] [Related]
19. Persistence of fluphenazine in plasma after decanoate withdrawal.
Gitlin MJ; Midha KK; Fogelson D; Nuechterlein K
J Clin Psychopharmacol; 1988 Feb; 8(1):53-6. PubMed ID: 3351000
[TBL] [Abstract][Full Text] [Related]
20. Clozapine and tardive dyskinesia.
Miller DD
Am J Psychiatry; 2003 Mar; 160(3):588. PubMed ID: 12611849
[No Abstract] [Full Text] [Related]
[Next] [New Search]
